Stock Track | Valneva SE Soars 7.55% on Positive Lyme Disease Vaccine Trial Data

Stock Track11-27

Valneva SE's stock surged 7.55% during intraday trading on Wednesday following the release of positive final data from a mid-stage study of its Lyme disease vaccine candidate, VLA15, developed in collaboration with Pfizer. The results showed sustained antibody levels across all six Lyme disease serotypes and age groups, with a favorable safety profile.

The vaccine candidate, VLA15, is the most advanced in development for Lyme disease, with analysts highlighting a high probability of success in late-stage trials. The findings support the potential for yearly vaccinations ahead of Lyme season, addressing a significant unmet medical need. This development positions Valneva as a key player in the biotech space, with the phase 3 trial results expected in the first half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment